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Prominent tasks of cysteine cathepsins involve endo-lysosomal proteolysis and turnover of extracellular
matrix constituents or plasma membrane proteins for maintenance of intestinal homeostasis. Here we
report on enhanced levels and altered subcellular localization of distinct cysteine cathepsins in adeno-
carcinoma tissue in comparison to adjacent normal colon. Immunoﬂuorescence and immunoblotting
investigations revealed the presence of cathepsin L in the nuclear compartment in addition to its ex-
pected endo-lysosomal localization in colorectal carcinoma cells. Cathepsin L was represented as the full-
length protein in the nuclei of HCT116 cells from which steﬁn B, a potent cathepsin L inhibitor, was
absent. Fluorescence activated cell sorting analyses with synchronized cell cultures revealed deceleration
of cell cycle progression of HCT116 cells upon inhibition of cathepsin L activity, while expression of
cathepsin L-enhanced green ﬂuorescent protein chimeras accelerated S-phase entry. We conclude that
the activity of cathepsin L is high in the nucleus of colorectal carcinoma cells because of lacking steﬁn B
inhibitory activity. Furthermore, we hypothesize that nuclear cathepsin L accelerates cell cycle pro-
gression of HCT116 cells thereby supporting the notion that cysteine cathepsins may play signiﬁcant
roles in carcinogenesis due to deregulated trafﬁcking.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cysteine cathepsins are proteases involved in numerous physi-
ological processes with a variety of tasks in protein processing and
degradationwithin endo-lysosomes besides the multiple roles they
play outside of endocytic compartments in more specialized cell
types [1e6]. In the gastrointestinal tract, cysteine cathepsins are
distributed in a segment-speciﬁc manner along its length [7].
Prominent tasks of cysteine cathepsins in mucosal cells relate to
maintenance of endo-lysosomal proteolysis for homeostasis of the
intestine. Moreover, the cathepsins B and L are important for pro-
cessing and turnover of a large variety of proteins ranging from
extracellular matrix constituents like collagen IV and laminin dur-
ing regeneration of the mucosa, to E-cadherin and occludin ofmhane), illukkum@embl.de
unhild.Mari.Malandsmo@rr-
gland.Haugen@rr-research.no
Heidelberg, Germany.
B.V. This is an open access article uadherens and tight junctions, respectively, as well as ecto-enzymes
such as aminopeptidase N in resting states of enterocytes [7e11].
The cysteine cathepsins also play signiﬁcant roles in different pa-
thologies including cancer, typically due to deregulation of their
expression levels and/or activity, subcellular distribution patterns,
or upon altered trafﬁcking [5,12e16]. These notions highlight that it
is critical to determine not only transcript levels or protein
amounts, but also the localization and sites of action of cysteine
cathepsins in order to understand their functions in situ
[2,4e6,12,13,16].
In early and late stages of carcinogenesis, both, cancer and non-
cancer stromal cells often over-express and/or over-secrete pro-
teases such as the cysteine cathepsins [12,13,16e20]. Eventually,
enhanced levels of secreted cysteine cathepsins can lead to exces-
sive extracellular matrix degradation thereby paving the way for
cancer cells to escape from the primary tumor sites and thus also
facilitating extravasation and invasion of distant tissue during
metastasis. However, several recent studies highlighted an addi-
tional unexpected site of action for cysteine cathepsins, namely the
nucleus. Cathepsin L, in particular, was proposed to mediate pro-
cessing of the transcription factor CUX1 in the nucleus of mousender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[21]. Similarly, cathepsin L-mediated processing of histone H3 was
hypothesized to direct differentiation of mouse embryonic stem
cells [22]. In contrast, we detected nuclear variants of the cysteine
cathepsins B and V, but not L, in the nuclei of thyroid carcinoma
cells where they are believed to be involved in the development of
thyroid malignancies through modiﬁcation of DNA associated
proteins [23]. Very recently, we were also able to show that a non-
cathepsin cysteine peptidase, AEP/legumain, is present in the nu-
cleus of colon carcinoma cells where it has been suggested to
contribute to histone H3.1 processing [24].
The ﬁndings listed above demonstrate that cysteine cathepsins
and variants thereof reach the nucleus of different cell types (for
review, see Ref. [6]). Moreover, some speciﬁcity seems to exist with
which cysteine cathepsins and their variants are sorted in distinct
cell types. Thus, cathepsin L has been proposed to be involved in
regulation of proliferation and differentiation of embryonic stem
cells and ﬁbroblasts, while variants of its closest relative cathepsin
Vwere sorted to the nuclei of hyper-proliferative thyroid carcinoma
cells. Hence, in the present study we asked whether cysteine ca-
thepsins L or V were sorted to the nucleus of colorectal carcinoma
cells, and if so, which molecular forms may enable intra-nuclear
activity.
2. Materials and methods
2.1. Cell culture and tissue microarrays
Intestine epithelial (IEC6) and the human colorectal carcinoma
(CRC) cell lines Caco2, SW620, and HCT116 obtained from ECACC
(Salisbury, UK) or ATCC (Teddington, Middlesex, UK) were cultured
at 37 C and 5% CO2 in Dulbecco's Modiﬁed Eagle's Medium with
4 mM L-glutamine (Lonza, Verviers, Belgium) and 0.1 U/mL bovine
insulin (SigmaeAldrich, Taufkirchen, Germany), Eagle's Minimum
Essential Medium (Biowhittaker™, Verviers, Belgium), and RPMI-
1640 (Biowhittaker™), all supplemented with 10% fetal calf
serum (Lonza), respectively.
Tissue microarrays (TMAs) consisted of colon adenocarcinoma
and cancer-adjacent normal colon tissue sections from patients
diagnosed with colon cancer at different tumor stages (Biomax,
Rockville, USA).
2.2. Construction of plasmids and transfection
The plasmid pEGFP-N1 (Clontech, Heidelberg, Germany) was
used for insertion of the cDNA coding for cathepsin L obtained from
HaCaT human keratinocytes yielding phCL-EGFP (see Figs. 1e4 in
Ref. [25]), following our strategy of GFP-tagging of endo-lysosomal
proteases as previously described in Ref. [26]. Transfection was
performed using X-treme GENE HP DNA transfection reagent
(Roche Diagnostics, Mannheim, Germany).
2.3. MTT assays
Cell proliferation rates andmetabolic activity levels of transfected
HCT116 cells were examined by a colorimetric assay determining 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
conversion rates [25,27].
2.4. Cell cycle synchronization
Arrest of HCT116 cells in G1/G0 phase was by incubation in
serum-free medium for 24 h, and cultures were analyzed after
chasing in complete medium for up to 24 h. Transfectionwas before
cell cycle arrest for 24 h. Treatment with 10 mM of the cellpermeable, irreversible cathepsin L inhibitor I, i.e. N-benzylox-
ycarbonyl-phenylalanyl-phenylalanine-ﬂuoromethyl ketone (Z-
Phe-Phe-FMK; Calbiochem® CAS 108005-94-3 through Merck
Biosciences GmbH, Darmstadt, Germany), was performed during
the chase period. This inhibitor was previously shown to specif-
ically target cathepsin L [28]. For synchronization in early S phase,
cells were incubated in 2 mM thymidine (SigmaeAldrich) for 18
and 17 h interrupted by a 9-h-incubation in complete medium. For
G2/M arrest, cells were treated with 2 mM thymidine for 18 h, and
released for 3 h by incubation in complete culture medium, before
they were incubated with 100 ng/ml nocodazole (SigmaeAldrich)
for another 12 h.
2.5. Immunoﬂuorescence labeling
Colon TMA slides were treated with xylol 5 times for 5 min,
each, followed by 5-min-washes with decreasing concentrations of
ethanol from 100% to 30% to remove the parafﬁn. To reduce auto-
ﬂuorescence, the slides were treated with freshly prepared so-
dium borohydride (1%; Carl Roth GmbH) before indirect immuno-
ﬂuorescence staining. Cells were ﬁxed and immunolabeled as
described before [29]. Speciﬁc primary antibodies were rabbit anti-
human cathepsin L (1:10; RD Laboratorien, Dieben, Germany, 06-
0007), mouse anti-human cathepsin V (1:50; R&D Systems, Min-
neapolis, USA, MAB1080), mouse anti-human steﬁn B (1:25;
Abcam, Cambridge, United Kingdom, ab54566), and rabbit anti-
human Ki67 (1:100; Abcam, ab15580). As secondary antibodies,
Alexa 488- and Alexa 546-coupled antibodies were used (1:200;
Molecular Probes, Karlsruhe, Germany), and 5 mM Draq5™ (Bio-
status Limited, Shepshed Leicestershire, UK) was applied for nu-
clear counter-staining. In negative controls, speciﬁc primary
antibodies were omitted.
2.6. Microscopy and image analysis
Immunolabeled cells and tissue sections were viewed with a
confocal laser scanning microscope (LSM 510 Meta and LSM 700,
Carl Zeiss Jena GmbH, Jena, Germany). Micrographs were taken at a
resolution of 1024  1024 pixels, and analyzed with standard LSM
510 or Zen 2012 software (Carl Zeiss Jena GmbH). For quantitation
of cysteine cathepsin levels in colon TMAs, three images from each
tissue section were obtained while keeping the same detector gain
and pinhole settings. Six normal and twelve adenocarcinoma
samples were used for the analysis. Image analysis of signals rep-
resenting nuclear localized cathepsins was performed on at least
ﬁve images from each preparation. By using CellProﬁler software,
signals of immunostaining intensities over the areas covered by the
nuclei were quantiﬁed by masking with the corresponding
Draq5™-positive area [24,30]. The same software was used to
determine the proliferation rates of normal intestine epithelial and
CRC cells as proportion of Ki67-positive cells of all cells.
2.7. FACS analysis
After the desired treatment and synchronization of HCT116 cells,
they were washed in PBS before ﬁxation in cold 70% ethanol for 1 h
at 4 C, and collected by centrifugation for 5 min at 500 g. The cell
pellets were washed twice with PBS, resuspended and incubated in
1 ml PBS containing 10 mg/ml propidium iodide, 10 mg/ml DNase-
free RNase, 5 mM MgCl2, 10 mM Tris, pH 7.5, at 37 C for 30 min.
The cellular DNA content of individual samples was determined
using FACS Calibur (Becton Dickinson) and the data was analyzed
using FlowJo software (Tree Star, Ashland, USA). The sum of all cells
counted was set to 100% and proportions of cells in G1/G0, S, and
G2/M were calculated as percentages.
Fig. 1. Altered localization and elevated levels of cysteine cathepsins in human
adenocarcinoma and normal colon tissue. Immunohistochemistry of normal human
colon (A, C) adjacent to adenocarcinoma tissue (B, D) after immunostaining of cathep-
sins L and V as indicated (green signals). Nuclei were counter-stained with Draq5™ (red
signals). The boxed areas in B and D are magniﬁed in B0 and D0 , respectively. Cathepsin-
speciﬁc signals were observed in vesicles (arrowheads), detected in re-association with
the apical plasma membrane domains (open arrowheads), and present in the nuclei of
mucosa cells (arrows). Scale bars represent 50 mm. Bars charts depicting quantitation of
immunoﬂuorescence intensities (E) of cathepsins L and V in adenocarcinoma (grey bars)
and normal colon tissue (open bars). Values are given as means ± standard deviations.
Levels of signiﬁcance are indicated as ** for p < 0.01.
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activity assays
Subcellular fractions were prepared and lysed in PBS containing
0.2% Triton X-100 as described before [29,31], normalized to equal
amounts of protein and loaded onto 12.5% or 8e18% gradient SDS-
polyacrylamide gels (GE Healthcare, 80-1255-53) along with a
PAGE ruler pre-stained protein ladder (Fermentas). After transfer
onto nitrocellulose, blots were incubated with rabbit anti-human
cathepsin L (1:1000; RD Laboratorien, 06-0007), rabbit anti-
human HMGB1 (1:300; Abcam, ab18256), and HRP-coupled sec-
ondary antibodies for subsequent visualization by using enhanced
chemiluminescence substrate on CL-XPosure ﬁlm (both from Pierce
through Perbio Science Europe, Bonn, Germany) [7].
The cathepsin L activity assays were performed in duplicates
and repeated at least twice as described before [31] with variations
detailed in Refs. [29,32,33]. In brief, subcellular fraction lysates
were assayed by monitoring cleavage of 5 mM cathepsin L-speciﬁc
substrate N-benzyloxycarbonyl-phenylalanyl-arginine-7-amido-4-
methylcoumarin (Z-Phe-Arg-AMC; Bachem Distribution Services
GmbH,Weil am Rhein, Germany) at pH 5.5 for 10min at 30 C in the
presence of 1.5 mM CA-074 (Merck Biosciences GmbH) as cathepsin
B-speciﬁc inhibitor. Negative controls were run in parallel with the
addition of 10 mM E64, a broad-spectrum cysteine peptidase in-
hibitor. Reactions were quantiﬁed by measuring the ﬂuorescence
with a Tecan GENios Reader (Tecan Deutschland GmbH) using an
excitation wavelength of 360 nm and emission reading at 465 nm.
2.9. Statistical evaluations
Statistical analysis was performed using standard computer
software and levels of signiﬁcance were determined by two-tailed,
unpaired Student's T-test using GraphPad Prism 5.04 (GraphPad,
San Diego, California, USA).
3. Results
3.1. Elevated levels of cysteine cathepsin L in adenocarcinoma of
colon tissue
In the present study, we used TMAs to compare adenocarcinoma
tissue with adjacent, normal colon tissue with regard to the
expression levels and localization of cysteine cathepsins. We
investigated the ubiquitously expressed cysteine cathepsin L and
cathepsin V, which is also referred to as cathepsin L2, as it is the
closest relative of cathepsin L [34,35]. The cathepsins were
immunolabeled on de-parafﬁnated sections and semi-
quantitatively determined in normal versus tumor tissue.
In epithelial cells of normal colon tissue, cathepsin L-speciﬁc
ﬂuorescence signals were detected within vesicles that were
abundant at the apical pole (Fig. 1A, arrowheads), whereas vesicles
containing cathepsin L were scattered throughout the cytoplasm in
adenocarcinoma cells (Fig. 1B). In addition, cathepsin L immuno-
positive signals were detected at the apical plasma membrane in
normal and adenocarcinoma tissue (Fig. 1A, B, open arrowheads).
Cathepsin L-speciﬁc antibodies also stained the nuclei of adeno-
carcinoma cells (Fig. 1B, B0, arrows). Interestingly, signals repre-
sentative of cathepsin L's presence in the nuclei were also observed
in normal tissue (Fig. 1A, arrow). Cathepsin V was detectable in a
vesicular pattern throughout the cytoplasm as well as in the nuclei
of cells in normal and adenocarcinoma tissue (Fig. 1C, D, D0).
Fluorescence intensity measurements revealed signiﬁcantly
elevated levels of cysteine cathepsin L in adenocarcinoma tissue
compare with normal adjacent tissue, whereas cathepsin V im-
munostaining signal intensities remained unaltered (Fig. 1E).These results pointed to elevated expression levels and differ-
ential localization of the cysteine cathepsin L, but not V, in malig-
nant compared to normal adjacent tissue. Because only cathepsin L
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in adenocarcinoma, we focused our further studies on this protease.
3.2. Nuclear localization of cathepsin L in normal intestine
epithelial and CRC cell lines
To investigate the molecular forms and subcellular localizationFig. 2. Nuclear localization of cathepsin L, but not steﬁn B in hyperproliferative colorectal ca
J), SW620 (C, G, K), and HCT116 cells (D, H, L) after immunostaining with antibodies agains
signals within nuclei. Scale bars represent 20 mm. M, N Bars charts depicting anti-cathepsi
normal IEC6 cells (open bars), and proliferative indices determined as percentages of K
means ± standard deviations. Levels of signiﬁcance are indicated as ** for p < 0.01, *** forof cathepsin L and its endogenous inhibitor steﬁn B in vitro, the
normal intestine epithelial cell line IEC6 was compared with the
CRC cell lines Caco2, SW620, and HCT116 in immunoﬂuorescence
and immunoblotting experiments.
Cathepsin L was localized in a reticular pattern in IEC6 cells,
while it was also present in ring-shaped structures within the
nuclei (Fig. 2A, arrows), thereby conﬁrming our previousrcinoma cell lines. A-L Confocal laser scanning micrographs of IEC6 (A, E, I), Caco2 (B, F,
t cathepsin L (AeD), steﬁn B (EeH), and Ki67 (IeL). Arrows highlight immunopositive
n L-positive signals over nuclear proﬁles of CRC cells (M, grey bars) in comparison to
i67-positive cells in continuous cell cultures as indicated (N). Values are given as
p < 0.001, and **** for p < 0.0001.
Fig. 3. Molecular forms of cathepsin L in intestine epithelial and CRC cell lines.
Immunoblot analyses of whole cell lysates of normal and CRC cell lines as indicated
after staining with cathepsin L-speciﬁc antibodies (A), while b-tubulin was used as a
loading control (B). Molecular mass markers are indicated in the left margins. Note,
that all cell lines featured the expected molecular forms, i.e. pro- (pro), single-chain
(SC), and the heavy chain (HC) of two-chain cathepsin L (A), while a high molecular
mass band of approx. 65 kDa appeared in the lysates of IEC6 cells, only. The relative
amounts of distinct cathepsin L forms as a proportion of total cathepsin L were
determined by densitometry (C), revealing an over-proportional abundance of two-
chain cathepsin L in SW620 and HCT116 cells, in particular.
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the CRC cell lines, cathepsin L immunostaining revealed reticular
patterns and numerous vesicles distributed throughout the cyto-
plasm, while immunostaining was in particular prominent in the
nuclei, and conﬁned to the nuclear matrix around the nucleoli
(Fig. 2BeD, arrows).
To maintain homeostasis in any cell type or tissue, a proper
balance of proteases and their endogenous inhibitors is important.
Steﬁn B, also referred to as cystatin B, is known to act as a counter-
player of a number of cysteine peptidases, while it is particularly
potent in inhibiting cathepsin L [36e39]. Hence, endogenous
cysteine peptidase inhibitors like steﬁn B act in safe-guarding
mammalian cells by their presence in the cyto- or nucleoplasm,
and thus protect from activities of proteolytic enzymes leaking into
the cytoplasm upon, for instance, non-intended rupture of endo-
lysosomes in pathological situations. As expected, immunoﬂuo-
rescence studies with normal intestine epithelial IEC6 cells
revealed cytoplasmic and nuclear localization of steﬁn B (Fig. 2E,
arrows). In clear contrast, CRC cells revealed only very faint
amounts of immunolabeled steﬁn B within their nuclei, while it
was prominently present within the cytoplasm of Caco2 and
SW620 cells, and mostly associated with the cytoplasmic face of
vesicles in HCT116 cells (Fig. 2FeH, green signals). Immunolabeling
of the proliferation marker Ki67 revealed high proliferation rates in
the CRC cells (Fig. 2JeL, yellow signals) but not in normal IEC6 cell
cultures (Fig. 2I), thereby reﬂecting the enhanced cathepsin L
expression in the nuclei of CRC cells (Fig. 2BeD, cf. A).
Next, we quantiﬁed the extents of nuclear localized cathepsin L
in the different cell lines using the semi-automated image analysis
tool CellProﬁler by setting up a pipeline that determined the signal
intensities over nuclear proﬁles of ﬁxed and permeabilized cells
after immunolabeling. Signiﬁcantly higher levels of cathepsin L-
speciﬁc immunopositive signals associated with nuclear proﬁles
were found in CRC cells in comparison to normal IECs (Fig. 2M).
These results supported those of the immunoﬂuorescence analyses
and suggested higher amounts of nuclear cathepsin L in CRC cells
than in normal intestine epithelial cells. Moreover, the results
revealed the presence of steﬁn B in the cytoplasm and nuclei of
normal intestine epithelial cells, in contrast to its absence from the
nuclei of CRC cells, which were characterized by high proliferation
rates (Fig. 2N).
3.3. Expression of full-length cathepsin L in normal intestine
epithelial and CRC cells
The identities of anti-cathepsin L-immunopositive signals were
analyzed next through immunoblotting studies with whole cell
lysates of IEC6, Caco2, SW620, and HCT116 (Fig. 3A, B, lanes 1e4,
respectively). Immunoblotting with cathepsin L-speciﬁc antibodies
revealed bands of apparent molecular masses representative of all
expected forms of the enzyme, namely the 38-kDa proform, the 30-
kDa single-chain (SC), and the 25-kDa heavy chain (HC) of the two-
chain form (Fig. 3A, lanes 1e4, pro, SC, and HC, respectively).
Determination of the relative amounts of these speciﬁc molecular
forms of cathepsin L was performed by densitometry (Fig. 3C). The
results showed that the heavy chain of the two-chain form of
cathepsin L was more prominent than the other molecular forms in
SW620 and HCT116 cells (Fig. 3A, C, HC cf. SC and pro). However, in
Caco2, the proform of cathepsin L was abundant and expressed to
equal amounts of each, SC and HC, as was also observed for IEC6
cells (Fig. 3A, C).
These results pointed to differential processing and maturation
of procathepsin L in IEC6 and Caco2 versus SW620 and HCT116 cells.
The results further suggested that the cysteine cathepsin L, which is
present in the nuclei of CRC cells (see Fig. 2), has the potential, inprinciple, to exhibit proteolytic activity therein. Taken together
with the notion of high amounts of cathepsin L detected in
adenocarcinoma versus normal intestine tissue (see Fig. 1), we hy-
pothesized that cathepsin Lwithin the nuclear compartment of CRC
cells might be involved in cell cycle progression.3.4. Cathepsin L during cell cycle progression of HCT116 cells
HCT116 cells were used for all further investigations because of
the high levels of single- and two-chain cathepsin L expression (see
Fig. 3A, C), and because the proportion of nuclear cathepsin L was
highest in this cell line amongst the tested CRC cells (see Fig. 2M),
while the endogenous inhibitor steﬁn B was absent from their
nuclei (see Fig. 2H). The localization of cathepsin L and its proteo-
lytic activity were studied in subcellular fractions prepared from
HCT116 cell cultures which were synchronized and arrested in the
G1/G0, S, and G2/M phases of the cell cycle by serum starvation for
24 h, a double thymidine block, and incubation with nocodazol,
respectively.
Immunoﬂuorescence labeling of synchronized HCT116 cell
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cathepsin L throughout the cell cycle. Immunostaining revealed
cathepsin L in vesicles conﬁned to the peri-nuclear region, while
the protease was additionally and prominently detected in the
nuclei of cells arrested in G1/G0 phase (Fig. 4A, arrows). HCT116
cells arrested in S phase featured anti-cathepsin L-positive signals
in a reticular staining pattern (Fig. 4B, arrowhead) in addition to
strong nuclear staining (arrows). During G2/M phase, vesicles
dispersed throughout the cytoplasmwere positively stained by the
cathepsin L-speciﬁc antibody (Fig. 4C).Fig. 4. Differential localization of cathepsin L during the cell cycle of HCT116 cells. Confocal laser scanning micrographs of HCT116 cells after synchronization in different cell cycle
stages, i.e. G1/G0 (A), S (B), and G2/M phase (C). Arrows indicate prominent nuclear localization of immunolabeled cathepsin L (green signals). Nuclei were counter-stained with
Draq5™ (red signals). Scale bars represent 20 mm.To analyze the respective molecular forms of cathepsin L during
cell cycle progression, immunoblotting was performed with whole
cell lysates (W) as well as lysosomal (Ly) and nuclear fractions (Nu)
of HCT116 cells that were arrested in different cell cycle stages
(Fig. 5). Enrichment of the respective subcellular fractions was
conﬁrmed by immunoblotting of high mobility group box 1
(HMGB1) protein as a marker of the cyto- and nucleoplasm, which
was absent from lysosomal but enriched in nuclear fractions as
expected (Fig. 5, bottom panels). During G1/G0 phase, cathepsin L
was, surprisingly, mainly detected in the nuclear fractions as the
heavy chain representing the two-chain form of the enzyme
(Fig. 5A, HC). Presence of cathepsin L as mature single- and two-
chain form peaked in all fractions in S phase of HCT116 cells
(Fig. 5B, cf. 5A and 5C). In cells arrested in G2/M phase, a band
representing the heavy chain of cathepsin L was most prominent in
the lysosomal fraction of HCT116 cells (Fig. 5C).
These results suggested that cathepsin L was localized to the
nucleus throughout all phases of the cell cycle, and interestingly,
the mature forms were the most abundant forms in the nuclear
fractions of HCT116 cells regardless of the cell cycle stage. Subse-
quently, whole cell lysates, lysosomal, and nuclear fractions of
HCT116 cells were assayed for cathepsin L activity (Fig. 6). Proteo-
lytic activities in the subcellular fractions prepared from differently
synchronized HCT116 cell cultures were compared to those ob-
tained from non-synchronized cells (Fig. 6, grey bars cf. white bars).
The results of the activity analyses supported the results obtained
by immunoﬂuorescence and immunoblotting, namely cathepsin L
activities of whole cell lysates and in lysosomal fractions were
highest during S phase followed by the levels measured in G2/M
phase (Fig. 6A, B). In contrast, the maximum of nuclear cathepsin L
activity was detected in HCT116 cells during G1/G0 phase (Fig. 6C).
Furthermore, a signiﬁcant increase over non-synchronized controls
was detected for nuclear cathepsin L activities of HCT116 cell cul-
tures during S and G2/M phase (Fig. 6C).
These ﬁndings were unexpected and suggested that cathepsin
L exhibited proteolytic functions that not only characteristically
dependent on its subcellular localization, i.e. within endo-lysosomes or nuclei of HCT116 cells, but also vary amongst spe-
ciﬁc cell cycle phases. Moreover, the highest lysosomal activities
of cathepsin L were measured during S phase, i.e. upon comple-
tion of G1/G0, when DNA replication takes place and other cellular
metabolism comes to a halt. In contrast, the nuclear activity of
cathepsin L reached a maximum in G1/G0 phase, i.e. before cells
enter S phase. These results suggested an involvement of
cathepsin L activity in facilitating S phase entry of HCT116 CRC
cells.3.5. Cathepsin L is essential for progression into S phase
To study the proposal of S phase entry promoted by cathepsin L
activity, we next analyzed the effects of cathepsin L inhibition on
cell cycle progression of HCT116 cells. For this purpose, subcon-
ﬂuent HCT116 cells were serum-starved for 24 h for synchroniza-
tion in G1/G0 phase, and treated with the cathepsin L-speciﬁc
inhibitor Z-Phe-Phe-FMK throughout the chase period. The
cathepsin L-inhibited cells were compared with non-treated con-
trols using ﬂuorescence-activated cell sorting (FACS) analyses.
Cell cultures in which cathepsin L was inhibited during the
chase period upon G1/G0-arrest displayed a much lower propor-
tion of cells in S phase at 16 h of chase compared to non-treated
controls (Fig. 7B cf. 7A), thereby suggesting that cathepsin L activ-
ity was essential for HCT116 cells to enter S phase. It is important to
note that cathepsin L inhibition did not affect the grossmorphology
of HCT116 cells as determined by microscopic inspection
(Suppl. Fig. 1).
These observations led us to propose a dependence of S phase
entry and cell cycle progression on cathepsin L activity, and
prompted us to conduct an over-expression study addressing the
effects of enhanced levels of cathepsin L on cell cycle progression.
3.6. Faster progression through the cell cycle upon cathepsin L
expression in HCT116 cells
For expression of full-length cathepsin L, which was tagged with
EGFP at its C-terminus, subconﬂuent cultures of HCT116 cells were
transiently transfected with the plasmid phCL-EGFP (see Fig. 4 in
Ref. [25]) for 24 h. Chimeric hCL-EGFP was detected in co-
localization with endogenous cathepsin L, thus exhibiting retic-
ular and vesicular localization (Fig. 7D’, arrowhead) in addition to
its prominent nuclear appearance (arrow), indicating co-trafﬁcking
of endogenous cathepsin L and expressed hCL-EGFP. We also
investigated the metabolic activities and proliferation rates of
HCT116 cells upon expression of phCL-EGFP using an MTT-assay in
comparison with non-transfected and cells transfected with the
Fig. 5. Differential expression of cathepsin L during the cell cycle of HCT116 cells. Immunoblots with cathepsin L-speciﬁc antibodies (top panels) of subcellular fractions prepared
from HCT116 cells after synchronization in different cell cycle stages, i.e. G1/G0 (A), S (B), and G2/M phase (C) revealed pro- (pro), single-chain (SC), and the heavy chain of two-
chain cathepsin L (HC) in whole cell lysates (W), lysosomal (Ly), and nuclear (Nu) fractions. Immunoblotting of HMGB1 (bottom panels) conﬁrmed fraction enrichment. Notably the
HC of cathepsin L was most prominently present in all preparations, i.e., whole cell lysates, lysosomal and nuclear fractions. Furthermore, cathepsin L amounts were highest in
nuclear fractions compared to lysosomal preparations of G1/G0-arrested cells, whereas lysosomal levels of cathepsin L protein exceeded those of the nuclear fractions when cells
were inspected in either S or G2/M phase.
Fig. 6. Differential activity levels of cathepsin L during the cell cycle of HCT116 cells. Bar charts are displayed that depict the means ± standard deviations of cathepsin L activity
levels as determined by cleavage of Z-Phe-Arg-AMC in the presence of CA-074 to inhibit cathepsin B which would also cleave this substrate efﬁciently. Quantiﬁcationwas performed
with the indicated preparations of synchronized HCT116 cell cultures (grey bars) in comparison with non-synchronized controls (open bars). Levels of signiﬁcance are indicated as *
for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. The results revealed highest levels of cathepsin L activity in lysosomal fractions during S phase, while the nuclear
cathepsin L activity peaked in G1/G0 phase.
T. Tamhane et al. / Biochimie 122 (2016) 208e218214pEGFP-N1 vector, alone. At 24 h post-transfection, the proliferation
rates and metabolic activities of HCT116 cells were highest in hCL-
EGFP-expressing cells as deduced from increased MTT conversion
rates in comparison to non-transfected controls or EGFP-expressing
cells (see Fig. 5 in Ref. [25]), however the differences did not reach
statistical signiﬁcance.
Next, HCT116 cell cultures were transiently transfected with
pEGFP-N1 and phCL-EGFP for 24 h, synchronized in G1/G0 phase,
and the proportion of cells in different phases of the cell cycle was
analyzed by FACS at different time points as indicated (Fig. 7C, D,
respectively). To determine the effect of vector alone on cell cycle
progression of HCT116 cells, pEGFP-N1 was used, which resulted in
values comparable to those determined in non-transfected cul-
tures, thus indicating that EGFP expression alone did not induce
any alteration of cell cycle progression of HCT116 cells (Fig. 7C cf.
Fig. 7A). Notably, however, expression of cathepsin L-EGFP caused
much faster progression through the cell cycle and accelerated
entry into S phase, because 25% of the transfected cells were in S
phase after 10 h already, while only 10% of the non-transfected cells
had entered S phase at the same time point (Fig. 7D, cf. 7A). As an
additional time interval, cells were inspected after 16 h as well,
which revealed only 12% of the hCL-EGFP-expressing HCT116 cells
remaining in S phase, while 44% of these cells had reached G2/M
phase already (Fig. 7D). These results indicated that cathepsin L is
involved in acceleration of S phase of HCT116 cells.
4. Discussion
Immunohistochemistry on tissue microarrays revealed
enhanced levels and altered localization of the cysteine cathepsin L,but not V, in adenocarcinomawhen compared to the distribution in
adjacent, normal colon tissue. Subsequently, localization and mo-
lecular forms of cathepsin L were examined in the CRC cell lines
Caco2, SW620, and HCT116 in comparison with the normal intes-
tine epithelial cell line IEC6. Because we detected considerable
protein amounts of cathepsin L in the nuclei of CRC cells, which also
featured a lack of the endogenous cathepsin L inhibitor steﬁn B,
detailed studies were conducted with synchronized HCT116 cell
cultures to shed light on the signiﬁcance of the nuclear localization
of this cysteine cathepsin through the cell cycle. By intervention
studies that employed cathepsin L inhibition and cathepsin L-EGFP
expression, proteolytically active cathepsin L was shown to accel-
erate cell cycle progression of HCT116 cells.
4.1. Nuclear cysteine cathepsin L in colorectal carcinoma
Cysteine cathepsins are important for intestine homeostasis
and for intestine epithelial cell integrity [7,8,11]. Alterations in
expression and localization patterns of these proteases can
contribute to gastro-intestinal pathologies such as post-operative
ileus (POI), ulcer formation, or tumor initiation and progression
[10,14,40]. Although cysteine cathepsins are known to mainly
serve as endo-lysosomal proteases, various studies provided evi-
dence for their alternative subcellular localization including the
nucleus [2,5,6,21e23,33]. Consistent with previous results from
our group, normal intestine epithelial IEC6 cells revealed nuclear
cathepsin L as ring-shaped structures, whereas cathepsin B, for
instance, was not detected in the nuclei of IEC6 cells [33].
Cathepsin L was localized to the nuclear compartment of HCT116
and SW620 cells, thereby also conﬁrming our previous
Fig. 7. Analysis of HCT116 cell cycle progression upon cathepsin L inhibition and expression of cathepsin L-EGFP chimeras. Cell cycle distribution of HCT116 cell cultures syn-
chronized in G1/G0 by serum-starvation was monitored by FACS analyses. The proportional distribution of cells in different cell cycle stages are depicted in bar charts for non-
treated cells (A), upon cathepsin L inhibition (B), or 24 h after transfection with pEGFP-N1 (C), and phCL-EGFP (D). The percentages of cells in the G1/G0, S, and G2/M phases of
the cell cycle were determined at 10 and 16 h of chase. Note that cathepsin L-inhibited HCT116 cells were delayed in progressing through the cell cycle even after 16 h of chase (B,
arrow). However, cathepsin L-EGFP expressing HCT116 cells progressed faster through the cell cycle (D, arrows) than non-transfected (A) and cells expressing EGFP alone (C).
Colocalization studies (D0 , yellow signals) were performed with HCT116 cells at 24 h after transfectionwith phCL-EGFP (green signals) and immunolabeling with cathepsin L-speciﬁc
antibodies (red signals). The arrow points to intra-nuclear cathepsin L, whereas the arrowhead depicts its cytoplasmic localization, demonstrating that cathepsin L-EGFP chimeras
were translocated efﬁciently to the nucleus of HCT116 cells. Scale bar represents 20 mm.
T. Tamhane et al. / Biochimie 122 (2016) 208e218 215investigations that identiﬁed cathepsin L as a constituent of the
nuclear soluble protein fraction of these cell lines [24]. This study
now provides evidence for the proteolytic activity of nuclear
cathepsin L in HCT116 cells, which peaked in G1/G0 phase while
still being well detectable during S and G2/M phase (see Fig. 6C).
Thus, we hypothesize that cathepsin L is involved in regulation of
cell cycle progression in HCT116 cells.
However, regulated activities of cysteine cathepsins in any
compartment require proper balancing by their endogenous in-
hibitors such as steﬁn B, which binds to a broad range of cysteine
peptidases including the cathepsins. Steﬁn B has been shown to
interact with cathepsin L in human glioblastoma cells, and elevated
steﬁn B levels lead to delayed cell cycle progression [41]. These
ﬁndings are consistent with the notion that cysteine peptidase
activities like those mediated by cathepsin L promote proliferation
of certain tumor cell types. Steﬁn B belongs to the class I cystatins,
i.e. it is typically found in the cytoplasm and in the nuclei of
mammalian cells [37,38], thus shielding against non-regulated
release of proteases into the cytoplasm due to unintendedrupture of endo-lysosomal membranes [4,6]. Interestingly, in this
study we show that steﬁn B expression was altered from mainly
nuclear in normal intestine epithelial cells to cytoplasmic in all the
examined CRC cell lines.
In line with the above mentioned ﬁndings, reports by us and
others have provided evidence for enzymatic activity of cysteine
cathepsins even at non-favorable conditions such as expected for
the cytoplasm, the extracellular space, and the nucleus
[2,6,24,31,41e47]. Moreover, we have shown previously that
mechanisms are in place, which enable differential regulation of
the proteolytic activities of cysteine cathepsins in DNA-rich envi-
ronments such as the nucleus [48].
Taken into account the abundance of cathepsin L within the
nuclei of CRC cells and considering the very low levels of their
endogenous inhibitor steﬁn B, we proposed and demonstrated that
nuclear cysteine cathepsin L in HCT116 cells is proteolytically active.
Thus, we were interested in its potential contribution to cell cycle
regulation and approached this hypothesis by using synchronized
HCT116 cell cultures.
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studies point to a role of intra-nuclear cathepsin L activities in
accelerating cell cycle progression
CRC cells lack the characteristic polarized structure and features
of differentiated enterocytes. The molecular mechanisms that
govern dedifferentiation processes during tumor initiation are
manifold and may well include altered processing of transcription
factors and DNA-associated proteins like histones. Consequently,
actions of intra-nuclear proteases could alter cellular regulation
also with regards to cell cycle progression [6,21e24,49,50].
In this study, active forms of cathepsin L were not only abundant
in the nuclear fractions of HCT116 cells during all cell cycle stages
but, more so, the results pointed to cell cycle stage-speciﬁc tasks.
And indeed, cathepsin L inhibition led to delayed S-phase entry of
HCT116 cells (see Fig. 7), pointing to important functions in
enabling cells to pass the related checkpoint. In support of this
proposal, we further showed that exogenous cathepsin L expres-
sion as an EGFP-tagged chimeric protein resulted in accelerated cell
cycle progression of HCT116 cells. Moreover, cathepsin L-EGFP was
sorted to the nuclear compartment thereby yielding enhanced
proliferation rates of HCT116 cells (see Fig. 7, and Fig. 5 in Ref. [25]).
Thus, cathepsin L activity can be considered a requirement of S-
phase entry in colorectal carcinoma such as modeled herein by
using HCT116 cell cultures.
An important question therefore arises namely, in how far
cathepsin L can become involved in regulation of cell cycle pro-
gression in both normal intestine epithelial and tumor cells, and
whether this phenomenon is ubiquitous. The latter question is
prompted by numerous observations indicating that cysteine
cathepsin related physiology and pathologies often exhibit cell
type-, tissue- and species-speciﬁc differences [for reviews, see
Refs. [2,4e6,16]]. Hence, cathepsin L-deﬁcient mice exhibit
deregulated proliferation and differentiation of epidermal kerati-
nocytes of the skin [51,52]. The underlying molecular cause has
been attributed to cathepsin L's role in processing growth factor
receptors resulting in their down-regulation upon internalization
[51]. Thus, the role that cathepsin L plays in regulating keratinocyte
proliferation is different from the task currently discussed, because
cathepsin L is strictly present within endosomes and lysosomes but
absent from the nucleus of keratinocytes [see Refs. [5, 51]]. More-
over, cathepsin L deﬁciency has been reported to promote tumor
progression in squamous cell carcinoma, which is similarly
believed to be due to its endo-lysosomal, anti-tumor function in
proteolytically terminating growth factor signaling [51,52]. In
contrast, the absence of cathepsin L resulted in reduced invasion
and proliferation rates of pancreatic islet cells [53] thereby sup-
porting the view that cathepsin L is a tumor-promoting protease.
However, a cathepsin L-like cysteine protease has also been shown
to be responsible for the degradation of sperm histones resulting in
disturbed DNA replication, which prevented early development of
sea urchin embryos by interfering with the initial mitotic divisions
[54,55]. Most important, important roles of cathepsin L in regula-
tion of cell proliferation under physiological circumstances can also
be inferred from its processing of CUX1, a transcription factor, in
mouse embryonic ﬁbroblasts [21,50] and its processing of histone
H3 in embryonic stem cell differentiation [22].
These observations and the ﬁndings of the present study point
to the necessity of investigating nuclear cysteine cathepsin activ-
ities further. It also indicates a certain lack of understanding,
namely the potential substrates and the underlying molecular
mechanisms of cathepsin targeting and transport in normal
epithelial and carcinoma cells remain elusive [see
Refs. [1,2,4e6,12,13,16,17]].4.3. Molecular mechanisms explaining nuclear localization of
cathepsins
In principle, biosynthesis and transport of cathepsins starts with
their co-translational import into the lumen of the rough endo-
plasmic reticulum (rER) and further transport to endo-lysosomal
compartments via the trans-Golgi network (TGN), where they
become activated either by autocatalysis or through processing by
other proteases including AEP/legumain acting at acidic conditions
[2,6,26]. However, cathepsins can also be trafﬁcked differently to
other cellular organelles like the nucleus, mitochondria, or the
extracellular space due to (i) transcript alterations caused by exon
skipping or alternative splicing, in addition to (ii) alterations in
translation through the use of alternative start sites resulting in N-
terminal truncation, and (iii) because of the presence of amino acid
sequences forming signal patches in alternative, speciﬁc molecular
forms that target for nuclear entry or mitochondrial localization
[2,6,56,57]. More recently, it was further shown that short forms of
cathepsin L are able to interfere with the translation of the full-
length protein [58]. However in this study, we observed nuclear
localization of cathepsin L in the CRC cell lines Caco2, SW620, and
HCT116 in its full-length form, indicating that it is not a trans-
lational defect that results in biosynthesis of alternate cathepsin L
forms, but rather the result of mistrafﬁcking. It is unclear at this
point how cathepsin L could reach the cytoplasm, but it can be
conceived that leaky endo-lysosomes are a likely explanation for its
escape from the endocytic compartments of CRC cells, which is
obviously enhanced in comparison to normal intestine epithelial
cells (see Fig. 2), perhaps due to different lipid compositions of the
membranes of CRC vs. normal epithelial cells.
A possible group of interaction partners that are destined to the
nucleus and could transport full-length cysteine cathepsins such as
cathepsin L from the cytoplasm into the nucleoplasm are the ser-
pins. These cross-class inhibitors of serine and cysteine peptidases
are expressed in the cytoplasm, and some serpins can enter the
nucleus mediated by their nuclear localization sequence (NLS).
Because serpins are known to interact with the closest relative of
cathepsin L, namely cathepsin V in vitro [41,48,49,59e61], one may
propose an interaction of full-length cysteine cathepsins with
cytoplasmic serpins that carry them in a hitch-hiking mechanism
and enable nuclear entry [23]. At the same time, interactions with
e.g. serpins reveal a mechanism for differential regulation of the
proteolytic activities of cysteine cathepsins in the DNA-rich envi-
ronment of the nucleus [48,61].
The role that cathepsin L plays in physiology or pathology,
regardless of its presence as full-length or speciﬁc form, depends on
more than its subcellular localization and its expression levels,
namely, how its activity might be regulated by potent endogenous
inhibitors and/or whether the protease is present in an activity-
supportive environment. Consequently, to better understand nu-
clear functions of proteases like cathepsin L, it will be critical to
determine their substrates in unusual locations of different cell
types. So far only few substrates of nuclear cysteine peptidases have
been identiﬁed, namely the transcription factor CUX, and the his-
tones H1 or H3 [21e24,41,50,57,59]; for review, see Refs. [6,17]. All
of the possible substrates suggested and veriﬁed thus far, point to a
potential task of nuclear cysteine peptidase activities in regulating
DNA conformation and/or transcription of proliferative cells
[48,60,61]. Hence, future studies will have to target the question
that remains with regard to the potential substrate(s) which nu-
clear cysteine cathepsin L might cleave within the nuclei of hyper-
proliferative HCT116 cells, thereby enabling them to progress faster
through the cell cycle. In this regard, interesting candidate sub-
strates for cysteine cathepsins are regulators of cell cycle
T. Tamhane et al. / Biochimie 122 (2016) 208e218 217progression that are required in G1 phase but which hinder S-phase
entry if present beyond the respective checkpoint [62,63].
We conclude that cathepsin L is present in the nucleus of CRC
cells in higher amounts than in normal intestine epithelial cells due
tomistrafﬁcking, and its proteolytic activity is high in the nucleus of
CRC cells because of the very low abundance of the endogenous
inhibitor steﬁn B. Cathepsin L also reaches the nucleus of normal
intestine epithelial cells, but to a much lower extent than in CRC
cells, and it is in such cells regulated by steﬁn B inhibition. We
hypothesize that in HCT116 cells, which progress faster through the
cell cycle than normal intestine epithelial cells, proteolytically
active cathepsin L engages with a nuclear substrate, which remains
elusive, enabling the cells to accelerate through the G1/S-
checkpoint. However, this latter proposal of cathepsin L-mediated
cell cycle regulator degradation in HCT116 cells requires future
investigations.
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